In a six-year study of older adults, having both abdominal obesity and low vitamin D was tied to more than double the risk of death — each condition amplifying the other.
Analyzing 20 years of U.S. health data, researchers found blood bicarbonate has crept up as CO2 climbed — a correlation they say warrants monitoring, not alarm.
In mice, an appetite-neuron protein called OPA1 guarded against overeating fat and obesity — and its loss hit females harder, hinting at more personalized obesity treatment.
Princeton researchers found that when fiber runs low, gut bacteria break down the intestine’s protective mucus — producing harmful byproducts linked to worse outcomes in disease.
The Venrock-led round backs a platform that lets self-funded employers contract, in one deal, with thousands of advanced primary-care practices that sit outside insurance networks.
The partnership will use quantum algorithms to design better photosensitizers — molecules that kill tumor cells when hit with light — a task classical computers struggle with.
Adding BioLife’s cell-preservation technology to its bioprocessing tools, Repligen is betting on vertical integration as cell and gene therapies scale up.
Whitehead Institute scientists found polyamines act as ‘storage lockers’ for iron — and draining them could poison cancer cells with their own iron.
Cambridge researchers found the obesity target GIPR works through two different brain regions — explaining why drugs that switch it on or off can both curb appetite.
A large study of over 21,000 women found those who used estrogen-only menopausal hormone therapy had less dementia and less Alzheimer’s pathology — but it’s an association, not proof.
Zipalertinib plus chemo so clearly slowed a hard-to-treat form of lung cancer that the trial was stopped early — setting up a fight with drugs from J&J and AstraZeneca.
A large proteomics analysis of a landmark Parkinson’s study is now public, aiming to sort patients into subtypes and speed more targeted, biology-driven therapies.